Trial Profile

Evaluation of safety and efficacy in mitapivat sulfate in adult patients with sickle cell disease

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mitapivat (Primary)
Indications Sickle cell anaemia
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms ESTIMATE

Most Recent Events

08 May 2026 Status changed from recruiting to active, no longer recruiting.
14 May 2025 According to an Agios Pharmaceuticals Media Release, data from this study will be featured during the 30th European Hematology Association (EHA) Congress (EHA 2025) in Milan, Italy, June 12-15, 2025.
12 Dec 2023 Results of the safety and efficacy of treatment with mitapivat in patients with SCD from the 1-year fixed-dose extension period , presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com